These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 4615788)

  • 1. Calusterone (NSC-88536): a poor substitute for fluoxy-mesterone (NSC-12165) in the treatment of advanced breast cancer.
    Falkson G; van Dyk JJ; van Eden EB; van der Merwe AM; FALKSON HC
    Cancer Chemother Rep; 1974; 58(6):939-41. PubMed ID: 4615788
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter: Calusterone (NSC-88536) in advanced breast cancer.
    Falkson G; Falkson HC
    Cancer Treat Rep; 1976 Mar; 60(3):220-1. PubMed ID: 130973
    [No Abstract]   [Full Text] [Related]  

  • 3. Calusterone therapy for advanced breast cancer.
    Aslam J; Maxwell I
    Cancer Treat Rep; 1977; 61(3):371-3. PubMed ID: 141327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calusterone (7beta,17alpha-dimethyltestosterone) as primary and secondary therapy of advanced breast cancer.
    Gordan GS; Halden A; Horn Y; Fuery JJ; Parsons RJ; Walter RM
    Oncology; 1973; 28(2):138-46. PubMed ID: 4583006
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical considerations on the use of a new synthetic androgen, Calusterone, in the treatment of advanced breast cancer].
    de Matteis A; Perrone V; Marone A
    Minerva Med; 1977 Jul; 68(36):2499-504. PubMed ID: 142218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calusterone.
    Brodkin RA; Cooper MR
    Ann Intern Med; 1978 Dec; 89(6):945-8. PubMed ID: 152592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of calusteron (NSC-88536) in advanced breast cancer.
    Rosso R; Porcile G; Brema F
    Cancer Chemother Rep; 1975; 59(5):890-1. PubMed ID: 128412
    [No Abstract]   [Full Text] [Related]  

  • 8. [Trial hormone therapy of advanced breast cancers with calusterone. Preliminary study of 41 cases].
    Brule G; Chauvergne J; Clavel B; Gary-Bobo J; Gurrin J; Klein T; Pommatau E
    Sem Hop; 1974 Dec 8-14; 50(50-51):3099-105. PubMed ID: 4377318
    [No Abstract]   [Full Text] [Related]  

  • 9. Cytotoxic drug and hormone therapy after adrenalectomy for advanced breast cancer.
    Keating JL; Yonemoto RH; Byron RL
    Surg Gynecol Obstet; 1968 Sep; 127(3):538-42. PubMed ID: 4969618
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical evaluation of 1,3-bis(2-chloroethyl)-nitrosourea (BCNU; NSC-409962) with fluoxymesterone (NSC-12165) in the treatment of solid tumors.
    Reyes ES; Talley RW; O'Bryan RM; Gastesi RA
    Cancer Chemother Rep; 1973 Apr; 57(2):225-30. PubMed ID: 4582564
    [No Abstract]   [Full Text] [Related]  

  • 11. Androgen therapy.
    Longson D
    Practitioner; 1972 Mar; 208(245):338-48. PubMed ID: 4557109
    [No Abstract]   [Full Text] [Related]  

  • 12. Calusterone treatment of breast cancer.
    Greenspan EM
    JAMA; 1972 Apr; 220(4):588. PubMed ID: 5067137
    [No Abstract]   [Full Text] [Related]  

  • 13. Studies of the combination of adriamycin and cyclophosphamide (alone or with other agents) for the treatment of breast cancer.
    Salmon SE; Jones SE
    Oncology; 1979; 36(1):40-7. PubMed ID: 156337
    [No Abstract]   [Full Text] [Related]  

  • 14. [Calusterone (7-beta, 17-alpha-dimethyltestosterone) in the palliative treatment of advanced breast cancer].
    Robustelli Della Cuna G; Bernardo G; Strada MR
    Minerva Med; 1977 Oct; 68(52):3555-63. PubMed ID: 74052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antitumoral activity of calusterone in advanced mammary carcinoma (author's transl)].
    Rosso R; Brema F; Porcile GF; Santi L
    Tumori; 1976; 62(1):79-84. PubMed ID: 138231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of adrenalectomy and androgen in disseminated mammary carcinoma.
    Dao TL; Nemoto T
    Surg Gynecol Obstet; 1965 Dec; 121(6):1257-62. PubMed ID: 4158865
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase II clinical trial of isophosphamide (NSC-109724) in patients with advances breast cancer.
    Ahmann DL; Bisel HF; Hahn RG
    Cancer Chemother Rep; 1974; 58(6):861-5. PubMed ID: 4615785
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of 5-azacytidine (NSC-102816) with CCNU (NSC-79037) in the treatment of patients with breast cancer and evaluation of the subsequent use of cyclophosphamide (NSC-26271).
    Cunningham TJ; Nemoto T; Rosner D; Knight E; Taylor S; Rosenbaum C; Horton J; Dao T
    Cancer Chemother Rep; 1974; 58(5 Pt 1):677-81. PubMed ID: 4138966
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of 7beta, 17alpha-dimethyltestosterone (calusterone) on cortisol metabolism in women with advanced breast cancer.
    Fukushima DK; Zumoff B; Bulkin W; Hellman L
    J Clin Endocrinol Metab; 1976 Jul; 43(1):38-45. PubMed ID: 133118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Male breast cancer: two cases with objective regressions from calusterone (7 alpha, 17 beta-dimethyltestosterone) after failure of orchiectomy.
    Horn Y; Roof B
    Oncology; 1976; 33(4):188-91. PubMed ID: 190574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.